Literature DB >> 15021055

Severe acute respiratory syndrome.

Jann-Tay Wang1, Shan-Chwen Chang.   

Abstract

PURPOSE OF REVIEW: Severe acute respiratory syndrome (SARS) is an infectious disease first recognized in November 2002 in Guangdong Province, China. It spread to many countries all over the world during February to June 2003, with 8098 cases reported. Twenty-one percent of the affected people were health care workers. Because SARS is a new emerging disease, this review describes the current understanding about the etiology, clinical pictures, laboratory and radiological findings of SARS. RECENT
FINDINGS: Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) was quickly found to be the etiological agent of SARS in April 2003. The transmission of SARS-CoV between human beings is mainly due to close contact. Using barrier precautions, the transmission of SARS-CoV can be prevented. The most common clinical presentations of patients with SARS include fever, cough, and dyspnea. The common laboratory findings include lymphopenia, thrombocytopenia, elevated serum alanine and aspartate aminotransferase, lactate dehydrogenase, creatine phosphokinase, and C-reactive protein. The most common radiological finding is pneumonic lesion(s) in the chest radiogram. Many patients experience exacerbation of clinical symptoms in the second week of disease course and some may progress to respiratory failure and need mechanical ventilatory support. The overall case fatality rate is 9.6%. The current method of treatment of SARS is still controversial.
SUMMARY: SARS is an infectious disease with high contagiousness and a high mortality rate. Early case identification and infection control are two important factors to limit its spread.

Entities:  

Mesh:

Year:  2004        PMID: 15021055     DOI: 10.1097/00001432-200404000-00013

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  16 in total

1.  When is quarantine a useful control strategy for emerging infectious diseases?

Authors:  Troy Day; Andrew Park; Neal Madras; Abba Gumel; Jianhong Wu
Journal:  Am J Epidemiol       Date:  2006-01-18       Impact factor: 4.897

2.  Longitudinal analysis of Severe Acute Respiratory Syndrome (SARS) coronavirus-specific antibody in SARS patients.

Authors:  Shan-Chwen Chang; Jann-Tay Wang; Li-Min Huang; Yee-Chun Chen; Chi-Tai Fang; Wang-Huei Sheng; Jiun-Ling Wang; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Clin Diagn Lab Immunol       Date:  2005-12

3.  Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.

Authors:  Anjeanette Roberts; Elaine W Lamirande; Leatrice Vogel; Benoît Baras; Geneviève Goossens; Isabelle Knott; Jun Chen; Jerrold M Ward; Ventzislav Vassilev; Kanta Subbarao
Journal:  Viral Immunol       Date:  2010-10       Impact factor: 2.257

4.  Bovine coronavirus nonstructural protein 1 (p28) is an RNA binding protein that binds terminal genomic cis-replication elements.

Authors:  Kortney M Gustin; Bo-Jhih Guan; Agnieszka Dziduszko; David A Brian
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

Review 5.  Lung epithelium as a sentinel and effector system in pneumonia--molecular mechanisms of pathogen recognition and signal transduction.

Authors:  Stefan Hippenstiel; Bastian Opitz; Bernd Schmeck; Norbert Suttorp
Journal:  Respir Res       Date:  2006-07-08

6.  SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 MAPK/STAT3 pathway.

Authors:  Shih-Wein Li; Ching-Ying Wang; Yu-Jen Jou; Tsuey-Ching Yang; Su-Hua Huang; Lei Wan; Ying-Ju Lin; Cheng-Wen Lin
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

7.  SARS Unique Domain (SUD) of Severe Acute Respiratory Syndrome Coronavirus Induces NLRP3 Inflammasome-Dependent CXCL10-Mediated Pulmonary Inflammation.

Authors:  Young-Sheng Chang; Bo-Han Ko; Jyh-Cherng Ju; Hsin-Hou Chang; Su-Hua Huang; Cheng-Wen Lin
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

Review 8.  The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.

Authors:  Hannah R Sharpe; Ciaran Gilbride; Elizabeth Allen; Sandra Belij-Rammerstorfer; Cameron Bissett; Katie Ewer; Teresa Lambe
Journal:  Immunology       Date:  2020-07       Impact factor: 7.397

Review 9.  COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus.

Authors:  Vladimir V Kouznetsov
Journal:  Eur J Med Chem       Date:  2020-07-15       Impact factor: 6.514

Review 10.  SARS vaccines: where are we?

Authors:  Rachel L Roper; Kristina E Rehm
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.